Alzheimers Research and Treatment Center

Wellington, Florida 33467

3 studies enrolling now · 26 studies all time

What they study most

Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer's Disease, Alzheimers Disease, Brain Diseases, Central Nervous System Diseases, Cognitive Dysfunction, Dementia, Early Preclinical Alzheimer's Disease, Lewy Body Disease, Mental Disorders, Mild to Moderate Alzheimer's Disease

Studies at this site

• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Recruiting now
• PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) — Running, not enrolling
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
• Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Running, not enrolling
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid — Running, not enrolling
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• Study of AV-1959D, an Amyloid Beta Vaccine — Running, not enrolling
• A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease — Completed
• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment — Completed
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• Bryostatin Treatment of Moderately Severe Alzheimer's Disease — Completed
• Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease — Running, not enrolling
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study of Gantenerumab in Participants With Mild Alzheimer Disease — Completed
• A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology — Completed
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
• Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease — Completed